Skip to main content
. 2018 Nov 8;23(1):205–215. doi: 10.1111/jcmm.13909

Figure 1.

Figure 1

miR‐520b is up‐regulated in NSCLC samples and exerts an oncogenic role in NSCLC cells. (A) Q‐PCR analysis of miR‐520b expression in 12 pairs of NSCLC samples and paratumour normal tissues (N, paratumour normal samples; C, cancer samples). (B) 3‐day MTT proliferation results of A549 cells with miR‐520b mimic or miR‐520b inhibitor treatment. (C) MTT assays of H1299 cells treated with miR‐520b mimic or miR‐520b inhibitor. (D) Wound healing assays of A549 cells treated with miR‐520b mimic or miR‐520b inhibitor. Quantification of wound closure at indicated time‐points was shown on the right. (E) Transwell assay of A549 cells treated with miR‐520b mimic or miR‐520b inhibitor. Numbers of invasive cells were shown on the right. Scale bar, 20 μm. All values are mean ± SD (n = 3, *P < 0.05,**P < 0.01 and ***P < 0.001)